The federally funded facility is part of a broader effort to establish Southern New Hampshire as a biomanufacturing hub.

Sam Altman's like all of us — he's aging. But a company he's backed wants it to stop. So could you pony up some cash at a $5 billion valuation?

Also check out Christmas at Kohl Holiday Boutique on the Palo Alto Patch calendar ...

Artificial intelligence is booming across biopharma, with deployed tech taking aim at the industry’s biggest challenges: the significant risk of failure, high costs and long development timelines. And ...

Beijing has repeatedly shown the world that it is willing to weaponize its dominance of supply chains, and President Donald Trump had to de-escalate the latest rare-earth dispute during his recent ...

Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple hematological malignancies CTD402 data for the treatment of ...

Picture a world where most life-saving medicines are discovered not in the United States, but in Beijing and Shanghai. Imagine a time when the most advanced biotechnologies — therapies that cure ...

The company, now owned by a Chinese conglomerate, is investing $150 million in 19 American suppliers across 10 states. By Farah Stockman Jones Plastic & Engineering, a Kentucky company that got its ...